Year: 2017
Type: preprint
Abstract: The anaplastic lymphoma kinase ( ALK ) gene plays an important physiologic role in the development of the brain and can be oncogenically altered in several malignancies, including non-small-cell lung cancer (NSCLC) and anaplastic large cell lymphomas (ALCL). Most prevalent ALK alterations are chromosomal rearrangements resulting in fusion genes, as seen in ALCL and NSCLC. In other tumors, ALK copy-number gains and activating ALK mutations have been described. Dramatic and often prolonged responses are seen in patients with ALK alterations when treated with ALK inhibitors. Three of these—crizotinib, ceritinib, and alectinib—are now FDA approved for the treatment of metastatic NSCLC positive for ALK fusions. However, the emergence of resistance is universal. Newer ALK inhibitors and other targeting strategies are being developed to counteract the newly emergent mechanism(s) of ALK inhibitor resistance. This review outlines the recent developments in our understanding and treatment of tumors with ALK alterations.
Source: Molecular Case Studies
DOI: 10.1101/mcs.a001115
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funders: Cancer Prevention and Research Institute of Texas, University of Texas MD Anderson Cancer Center, Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, National Cancer Institute, National Center for Advancing Translational Sciences, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
Awards: G122915289, Informatics to enable routine personalized cancer therapy, G1468253849, G1543354196, G2198050828, G2215946451, G293715275, G3191371094, G3203699377, G3880756689, G4276892241, G4705084763, G496938529, G4978893582, G580208524, G5819141951, Precision Oncology Decision Support Core, G7436411625, G788993117, G8692209788, G8941877087
OpenAlex ID: W2565081035